TrialEBioMedicine2018

Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.

Jagdeep Nanchahal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.